Surgical Robotics Technology
new generation surgical displays

Virtual Incision Appoints Piet Hinoul as CMO

virtual incision chief medical officer

Virtual Incision Corporation announces the appointment of global healthcare executive Piet Hinoul, MD, PhD, as chief medical officer (CMO). The company’s current CMO Dmitry Oleynikov, MD, FACS will take on the newly established role of chief surgeon, focusing on the research and development of new RAS technology. The expansion of the team strengthens Virtual Incision at a transformative point in its trajectory as it develops new market growth strategies for its MIRA Surgical System.

In addition to Dr. Oleynikov’s current role as the chair of the Department of Surgery at Monmouth Medical Center, he will continue to support Virtual Incision’s efforts in the area of robotic-assisted minimally invasive general surgery under his new role as chief surgeon. He has contributed to over 200 peer-reviewed articles, 250 abstract presentations, 11 issued patents, and 42 patent applications in the area of surgical robotics and surgical outcomes research. He was a critical stakeholder in the development of the MIRA Surgical System alongside Shane Farritor, MS, PhD, co-founder and chief technology officer of Virtual Incision.

“During Dr. Oleynikov’s tenure as CMO, we have evolved into a mature company with a miniaturized system that has the potential to impact millions of patients,” said John Murphy, president and chief executive officer of Virtual Incision. “We’re thankful for his continued contributions to Virtual Incision and his dedication to helping make MIRA a reality.”

Dr. Hinoul brings 30 years of healthcare experience to Virtual Incision, of which the past 15 have been spent in the MedTech industry. Most recently, Dr. Hinoul served as senior vice president and global head of medical affairs for the oncology company Novocure (NASDAQ: NVCR). Prior to that, he was the global head of preclinical, clinical, and medical affairs for Ethicon, Inc., the surgical subsidiary of Johnson & Johnson (NYSE: JNJ). Beyond his industry expertise, Dr. Hinoul is a European board-certified gynecologist with 15 years of clinical practice. He is widely published and has lectured internationally in the fields of urogynecology, surgery, and medical device innovation.

“Clinical excellence has served as the bedrock of Virtual Incision since its inception in 2006, and our commitment to that excellence is reinforced by the addition of Dr. Hinoul to our leadership team,” said John Murphy. “He is an accomplished global physician executive with a demonstrated track record of success. I am confident Dr. Hinoul’s broad experience with post-market medical affairs activities, in addition to his clinical background in women’s health, will critically boost our ability for future planning and execution in the U.S. and internationally on a variety of indications for MIRA.”

Source: Virtual Incision

Surgical Robotics Technology

Join thousands of Surgical Robotics Experts and get the latest updates straight to your inbox!